Luis R. Alejandri-Balleza
Guadalajara, JAL 44340, Mexico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Bidirectional Interactions Between Cervicovaginal Microbiota and Human Papillomavirus Drive Persistence and Disease Progression.
Journal: International journal of molecular sciences
Published: April 16, 2026
Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.
Journal: International journal of molecular sciences
Published: March 11, 2026
The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions.
Journal: Microorganisms
Published: February 10, 2026
Opposing profiles of Netrin-1 and adiponectin in metabolic inflammation and insulin resistance.
Journal: Frontiers in pharmacology
Published: May 21, 2025
Empagliflozin Leads to Faster Improvement in Arterial Stiffness Compared to Dapagliflozin: A Double-Blind Clinical.
Journal: Life (Basel, Switzerland)
Published: March 19, 2025
Microbiota and Inflammatory Markers: A Review of Their Interplay, Clinical Implications, and Metabolic Disorders.
Journal: International journal of molecular sciences
Published: January 13, 2025
Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. J. Cardiovasc. Dev. Dis. 2024, 11, 182.
Journal: Journal of cardiovascular development and disease
Published: August 20, 2024
Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial.
Journal: Journal of cardiovascular development and disease
Published: April 29, 2024
Decoding the Gut Microbiota-Gestational Diabetes Link: Insights from the Last Seven Years.
Journal: Microorganisms
Published: March 27, 2024
Showing 1-9 of 9
Last Updated: 09/26/2026